Description
Multiple participants noted the conflation of cellular dysfunction with senescence, but specific biomarkers to differentiate senescent from reactive astrocytes/microglia remain undefined. This is critical for therapeutic targeting specificity.
Source: Debate session sess_sda-2026-04-01-gap-013 (Analysis: sda-2026-04-01-gap-013)
Resolution criteria
Resolved when a validated multiplex panel (flow cytometry or spatial transcriptomics in post-mortem human brain, n >= 10 donors per group) distinguishes senescent from reactive glia using >=4 independent markers with AUC >= 0.80 each: (1) p16INK4a or p21CIP1 protein, (2) SA-beta-galactosidase activity, (3) SASP components (IL-6, MMP3 by multiplex ELISA or smFISH), and (4) absence of proliferation markers (Ki67-). Panel validated against scRNA-seq reference dataset (n >= 5,000 cells). Deliverable: panel protocol published in methods journal (e.g., Nature Protocols); reference scRNA-seq dataset deposited in GEO; SciDEX wiki page ‘Senescence vs Reactive Glia Markers’ updated.